Abstract
Stroke is a leading cause of long-term neurological disability and death worldwide. Traditional neurorehabilitation methods result in full recovery for less than 15% of stroke patients, highlighting the need for innovative approaches. Low-intensity transcranial focused ultrasound stimulation (tFUS) has emerged as a promising non-invasive neuromodulation technique with high focality and deep tissue penetration. This study evaluates the feasibility, safety and efficacy of tFUS for motor rehabilitation in ischemic stroke patients. We conducted a single-group prospective pilot study involving two stroke patients who received tFUS targeting the motor cortex contralateral to the lesion site three times a week. Patients were evaluated using multiple clinical measures of motor function. Both patients showed improvements in the Fugl-Meyer Assessment upper extremity score, kinesthetic sensation, stereognosis score from the Nottingham Sensory Assessment, and the Modified Barthel Index score. Follow-up evaluations immediately and three weeks after stimulation indicated sustained motor function improvements. The results suggest that tFUS can effectively enhance motor recovery in stroke patients without adverse events. This study provides robust evidence supporting the potential of tFUS in stroke rehabilitation, opening new avenues for clinical application and research.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
KCT0008320
Funding Statement
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2022R1A2B5B02001673), Korea-UK (MRC) Cooperative Development Program from the NRF, funded by the Korean government (Ministry of Science and ICT) (RS-2023-00303540), and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number : HI21C1260). This international project was supported by an MRC-NRF International Partnering Award (MC_PC_23032). J.J was supported by the AMS Springboard (SBF007\100077). J.J. and M.A.L.R. were supported by the EPSRC & MRC funded NEUROMOD+ (BMPF_PSM694).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of Korea University Anam Hospital (approval no. 2023AN0046) and was registered with the Clinical Research Information Service (registration no. KCT0008320).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵□ Joint first authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
